Bain Capital Life Sciences Investors LLC Invests $43.55 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,470,214 shares of the company's stock, valued at approximately $43,551,000. Olema Pharmaceuticals makes up 5.1% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its 7th biggest holding. Bain Capital Life Sciences Investors LLC owned 13.04% of Olema Pharmaceuticals at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Olema Pharmaceuticals by 6.0% during the 4th quarter. Vanguard Group Inc. now owns 2,685,009 shares of the company's stock valued at $15,654,000 after acquiring an additional 152,117 shares during the period. State Street Corp lifted its position in Olema Pharmaceuticals by 1.1% during the third quarter. State Street Corp now owns 1,969,963 shares of the company's stock valued at $23,521,000 after purchasing an additional 21,986 shares during the period. Pictet Asset Management Holding SA boosted its holdings in Olema Pharmaceuticals by 12.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company's stock worth $10,980,000 after purchasing an additional 215,895 shares during the last quarter. Candriam S.C.A. grew its position in Olema Pharmaceuticals by 3.0% in the 4th quarter. Candriam S.C.A. now owns 1,551,562 shares of the company's stock worth $9,046,000 after purchasing an additional 44,798 shares during the period. Finally, Wellington Management Group LLP raised its stake in Olema Pharmaceuticals by 52.1% during the 4th quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock valued at $8,839,000 after buying an additional 522,799 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Oppenheimer restated an "outperform" rating and set a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, March 28th.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock traded down $0.19 during trading hours on Friday, reaching $4.91. 719,271 shares of the company traded hands, compared to its average volume of 861,538. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $16.62. The company has a market cap of $335.52 million, a P/E ratio of -2.24 and a beta of 2.10. The firm has a 50-day moving average price of $4.20 and a 200 day moving average price of $6.84.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.12. Sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.